Skip to main content

Metastatic Colorectal Cancer C6461003

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Roseville
  • Berkeley
  • Sunnyvale
  • Fremont
  • Santa Rosa
  • Palo Alto
  • San Mateo

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Dron Gauchan, M.D.
Dron Gauchan, M.D.
Principal investigator
View profile

Sub-Investigators

Natalia Colocci, M.D., Ph.D., Zeyad H Kanaan, M.D., Julian H McLain, M.D., Kim-Son Nguyen, M.D., MPA, Uma Suryadevara, M.D., Huan T Ha, M.D.

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Colon Cancer GI008

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Colorectal Cancer Stage II/III ctDNA+ BNT122-01

    A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection

    Status: Open to Enrollment

  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB

    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?